HCV - Sustained Viral Response



Utility of Virological Response at Weeks 4 and 12 in the Prediction of SVR in Genotype 2/3 Patients: ACCELERATE Trial Results  11/07/06
More Frequent Dosing of Pegasys/Ribavirin Improves SVR Rate in Prior Non-responder Genotype 1 HCV Patients with Severe Fibrosis  11/07/06
Baseline HCV RNA Level of 400,000 Is Optimal Cut-off Point to Differentiate Low and High Probability of SVR  11/07/06
A la Carte Therapy More Cost-effective than Standard Combination Therapy for Treatment-naive Patients with Chronic Hepatitis C  11/07/06
Consistent SVR Rates across All Weight Categories in the Canadian POWeR Program  11/07/06
PegIntron plus Ribavirin in HCV Genotype 1 Patients with Slow Virological Response: Analysis of Early Enrollers in the SUCCESS Study  11/07/06
Treatment Extension to 72 Weeks of PegIntron plus Weight-based Ribavirin Improves SVR Rates in Difficult-to-Treat Slow Responders with Genotype 1  11/03/06
HCV RNA Negativity after 12 Weeks of Therapy Is the Best Predictor of SVR in Re-Treatment of Non-Responders: The EPIC3 Program  11/03/06
In ACCELERATE Trial, Highest SVR Seen in Patients Who Received the Longest Duration of Therapy with Pegasys and the Highest Mean Dose of Ribavirin Based on Body Weight  11/03/06
Sustained Virological Response to PegIntron Plus Ribavirin in Asian and Hispanic Patients  11/03/06
Baseline HCV RNA of 400,000 Best Predicts SVR and Relapse Rates in Patients Treated with Pegasys plus Ribavirin  11/03/06
An Interim Analysis of the Canadian POWeR Program (Pegetron Prospective Optimal Weight-Based Dosing Response): Consistent SVR Rates Across All Weight Categories
P Marotta and others. Poster #358.





Google_______________


 

 

 

 

 

 

 

 

 


Conference
Main Page


Hepatitis C
FDA-Approved
Treatments

Monotherapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron


Combination
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Hepatitis B
FDA-Approved
Treatments

Baraclude
Epivir-HBV
Hepsera
Intron A
Pegasys
Tyzeka